Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 86%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
8,756
Total Claims
$1.1M
Drug Cost
435
Beneficiaries
$2,565
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 218,535 Nurse Practitioner providers
-30%
Opioid rate vs peers
2.6% vs 3.8% avg
+118%
Cost per patient vs peers
$2,565 vs $1,174 avg
+77%
Brand preference vs peers
15.7% vs 8.9% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
2.6%
Opioid Rate
232
Opioid Claims
$3,953
Opioid Cost
5.6%
Long-Acting Rate
Brand vs Generic
Brand: 1,361 claims · $867K
Generic: 7,296 claims · $243K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 250 | $111K |
| Ixekizumab | 12 | $85K |
| Dapagliflozin Propanediol | 144 | $72K |
| Dulaglutide | 48 | $67K |
| Apremilast | 26 | $57K |
| Semaglutide | 41 | $46K |
| Sitagliptin Phosphate | 66 | $35K |
| Fluticasone/Umeclidin/Vilanter | 37 | $33K |
| Insulin Glargine,hum.Rec.Anlog | 77 | $31K |
| Empagliflozin | 47 | $24K |
| Rivaroxaban | 46 | $21K |
| Insulin Degludec | 29 | $20K |
| Mirabegron | 23 | $16K |
| Insulin Degludec | 17 | $13K |
| Sacubitril/Valsartan | 13 | $12K |
Prescribing Profile
Patient Profile
76
Avg Age
46%
Female
1.37
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About